Pharma Deals Review, Vol 2009, No 2 (2009)

Font Size:  Small  Medium  Large

Merck Serono Signs Multiple Sclerosis Deal with Ambrx

Taskin Ahmed

Abstract


Merck Serono has bought the rights to ARX424, an experimental multiple sclerosis drug, from Ambrx. The companies are already collaborating on another drug, the growth hormone, ARX201. Merck Serono also took an undisclosed equity stake in Ambrx.

Full Text: html

Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.